Antibodies directed to HER-3 and uses thereof

Details for Australian Patent Application No. 2012204099 (hide)

Owner Amgen Inc. U3 Pharma GmbH

Inventors Rothe, Mike; Borges, Eric; Radinsky, Bob; Freeman, Dan; Hartmann, Susanne; Treder, Martin

Agent Davies Collison Cave

Pub. Number AU-A-2012204099

Parent 2006332065

Filing date 11 July 2012

Wipo publication date 2 August 2012

International Classifications

C07K 16/28 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61K 39/395 Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 Antineoplastic agents

C07K 14/43 Peptides having more than 20 amino acids

C07K 16/32 Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

26 July 2012 Complete Application Filed

2 August 2012 Application Open to Public Inspection

  Published as AU-A-2012204099

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012204100-Functionalized magnetic nanoparticles and methods of use thereof

2012204098-Use of follistatin to increase muscle mass